Poor adherence to P2Y12 antagonists increased cardiovascular risks in Chinese PCI-treated patients

被引:4
|
作者
Sun, Yang [1 ]
Li, Chenze [1 ]
Zhang, Lina [1 ]
Hu, Dong [1 ]
Zhang, Xudong [1 ]
Yu, Ting [1 ]
Tao, Min [1 ]
Wang, Dao Wen [1 ]
Shen, Xiaoqing [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Div Cardiol, Dept Internal Med,Tongji Med Coll, Wuhan 430030, Peoples R China
基金
中国国家自然科学基金;
关键词
acute coronary syndromes; adherence to secondary prevention medications; clinical outcome; ACUTE MYOCARDIAL-INFARCTION; ELUTING STENT IMPLANTATION; ANTIPLATELET THERAPY; SECONDARY PREVENTION; MEDICATION ADHERENCE; 1ST YEAR; DISCONTINUATION; DISEASE; PREDICTORS; MORTALITY;
D O I
10.1007/s11684-017-0502-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Low adherence to secondary prevention medications (ATM) of patients after acute coronary syndrome (ACS) is associated with poor clinical outcomes. However, literature provides limited data on assessment of ATM and risks associated with poor in Chinese patients with ACS. In the current work, ATM was assessed in consecutively recruited patients with ACS in Tongji Hospital from November 5, 2013 to December 31, 2014. A total of 2126 patients were classified under low adherence (proportion of days covered (PDC) < 50%) and high adherence (PDC > 50%) groups based on their performance after discharge. All patients were followed up at the 1st, 6th, and 12th month of discharge while recording ATM and major adverse cardiac events (MACE). Bivariate logistic regression was used to identify the factors associated with ATM. Cox regression was used to analyze the association between ATM and MACE within one year after discharge. Results showed that coronary artery bypass grafting (CABG) alone had significantly lower proportion of high adherence to P2Y12 antagonists (83.0% vs. 90.7%, P < 0.01) than patients treated with percutaneous coronary intervention (PCI) only. Moreover, in patients undergoing PCI, high adherence to P2Y12 antagonists decreased the risk of MACE (hazard ratio = 0.172, 95% confidence interval: 0.039-0.763; P = 0.021). In conclusion, PCI-treated patients are more prone to remaining adherent to medications than CABG-treated patients. High adherence to P2Y12 antagonists was associated with lower risk of MACE.
引用
收藏
页码:53 / 61
页数:9
相关论文
共 50 条
  • [1] Poor adherence to P2Y12 antagonists increased cardiovascular risks in Chinese PCI-treated patients
    Yang Sun
    Chenze Li
    Lina Zhang
    Dong Hu
    Xudong Zhang
    Ting Yu
    Min Tao
    Dao Wen Wang
    Xiaoqing Shen
    Frontiers of Medicine, 2017, 11 : 53 - 61
  • [2] New P2Y12 antagonists
    Michelson, Alan D.
    CURRENT OPINION IN HEMATOLOGY, 2009, 16 (05) : 371 - 377
  • [3] In PCI-treated ACS, switching from aspirin + a newer P2Y12 blocker to aspirin plus clopidogrel reduced adverse events
    Lowenstern, Angela
    Newby, L. Kristin
    ANNALS OF INTERNAL MEDICINE, 2017, 167 (06) : JC28 - JC28
  • [4] The future of P2Y12 receptor antagonists
    Thomas, Mark R.
    Storey, Robert F.
    PLATELETS, 2015, 26 (05) : 392 - 398
  • [5] Optimizing platelet P2Y12 inhibition for patients undergoing PCI
    Steinhubl, Steven
    Roe, Matthew T.
    CARDIOVASCULAR DRUG REVIEWS, 2007, 25 (02): : 188 - 203
  • [6] Effect of pretreatment with P2Y12 receptor antagonists on mortality in patients undergoing PCI - A report from SCAAR
    Yan Wenwen
    Wang, Lemin
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (16) : C100 - C100
  • [7] Effect of pretreatment with P2Y12 receptor antagonists on mortality in patients undergoing PCI: A report from SCAAR
    Omerovic, E.
    Dworeck, C.
    Haraldsson, I.
    Ioanes, D.
    Odenstedt, J.
    Petursson, P.
    Robertsson, L.
    Stewart, J.
    Wahlin, M.
    Volz, S.
    Albertsson, P.
    Ramunddal, T.
    EUROPEAN HEART JOURNAL, 2016, 37 : 378 - 378
  • [8] A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs
    Wei Eric Wang
    Hongyong Wang
    Xukai Wang
    Chunyu Zeng
    Journal of Thrombosis and Thrombolysis, 2014, 37 : 102 - 106
  • [9] A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs
    Wang, Wei Eric
    Wang, Hongyong
    Wang, Xukai
    Zeng, Chunyu
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2014, 37 (02) : 102 - 106